We hypothesize this is because CD4+ anti-TGF-β CAR T cells lysed cancer cells, prevented exhaustion of CD8+ conventional CAR T cells, and improved the CD8+ conventional CAR T cells’ efficacy. This evidence concerns the gene CD8A and cancer.